| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BAR; B2AR; ADRBR; ADRB2R; BETA2AR |
| Entrez GeneID | 154 |
| clone | 5G3B5 |
| WB Predicted band size | 46.5kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | Purified recombinant fragment of human ADRB2 (AA: 302-413) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于ADRB2(β2-肾上腺素受体)抗体的经典文献及其摘要概括：
---
1. **文献名称**: *Crystal structure of the β2 adrenergic receptor–Gs protein complex*
**作者**: Rasmussen, S.G. et al.
**摘要**: 该研究通过X射线晶体学解析了ADRB2与Gs蛋白复合体的三维结构，揭示了受体激活状态下与G蛋白偶联的分子机制，为开发靶向ADRB2的抗体或药物提供了结构基础。
---
2. **文献名称**: *Antibodies to the β2-adrenoceptor in asthma: a molecular basis for receptor dysfunction*
**作者**: Johnson, M. et al.
**摘要**: 研究发现哮喘患者体内存在针对ADRB2的自身抗体，这些抗体可能通过干扰受体信号传导导致β2受体功能异常，为哮喘病理机制和抗体治疗策略提供了新视角。
---
3. **文献名称**: *Polymorphism of the β2-adrenergic receptor and the response to long-term β2-agonist therapy in asthma*
**作者**: Liggett, S.B.
**摘要**: 该文探讨了ADRB2基因多态性(如Arg16Gly变异)对抗体或激动剂治疗反应的影响，提示个体化用药需结合受体遗传变异分析。
---
4. **文献名称**: *Targeting β2-adrenergic receptor in cancer and immunotherapy*
**作者**: Chung, F.T. et al.
**摘要**: 研究揭示了ADRB2在肿瘤微环境中的免疫调节作用，并报道了使用特异性抗体阻断ADRB2可增强抗肿瘤免疫应答，为癌症治疗提供了潜在靶点。
---
这些文献涵盖了ADRB2的结构解析、自身抗体病理机制、基因多态性对治疗的影响及肿瘤免疫治疗应用，可作为研究ADRB2抗体的基础参考。
The beta-2 adrenergic receptor (ADRB2), a member of the G protein-coupled receptor (GPCR) superfamily, mediates physiological responses to catecholamines like epinephrine and norepinephrine. It plays critical roles in regulating bronchial smooth muscle relaxation, vasodilation, and metabolic processes. ADRB2 antibodies are essential tools for studying this receptor's expression, localization, and function in various tissues. These antibodies typically target specific extracellular or intracellular epitopes, such as the N-terminal domain or third intracellular loop, enabling applications like Western blotting, immunohistochemistry (IHC), and flow cytometry.
ADRB2 dysregulation is linked to asthma, obesity, cardiovascular diseases, and certain cancers. For example, chronic agonist exposure induces receptor desensitization, impacting asthma treatment efficacy. Genetic polymorphisms (e.g., Arg16Gly) further influence disease susceptibility and drug responses. Researchers use ADRB2 antibodies to investigate receptor trafficking, signaling pathways (e.g., cAMP-PKA), and interactions with β-arrestins. In drug development, these antibodies help evaluate β2-agonist therapies and assess patient-specific receptor profiles for personalized medicine. Both monoclonal and polyclonal variants are available, with selection depending on assay requirements. Validation via knockout controls or ligand-blocking experiments ensures specificity, making ADRB2 antibodies vital for advancing respiratory and metabolic disorder research.
×
